Orexo
10,08 SEK +1,82 %Vær den første som følger denne virksomhed
Orexo develops drugs and digital therapies that meet needs, especially in the area of mental health and diseases related to drug and drug abuse. The products are commercialized by Orexo in the USA or through partners all over the world. The main market is the American market for buprenorphine / naloxone products, where Orexo commercializes the main drug Zubsolv®, for the treatment of opioid dependence. The head office, where research and development work is conducted, is located in Uppsala.
Omsætning
624,3 mio.
EBIT %
-29,46 %
P/E
-
Udbytteafkast, %
-
Kursmål
-
Anbefaling
-
Opdateret
-
NASDAQ Stockholm
ORX
Daglig lav / høj pris
10,08 / 10,2
SEK
Markedsværdi
349,88 mio. SEK
Aktieomsætning
10,68 t SEK
Volumen
1,1 t
Seneste videoer
Finanskalender
Delårsrapport
18.07.2023
Delårsrapport
02.11.2023
Årsrapport
25.01.2024
Viser Alle indholdstyper
